Recurrent spontaneous abortion in early pregnancy (RSA) is a common disease in the field of gynecology, and the causes of RSA are complex, including genetic factors, endocrine disorders, uterine abnormalities, infections, immune factors, etc., of which immune factors account for the majority, 50-60%. From the perspective of transplantation immunology, pregnancy is a kind of semi-allogeneic immune transplantation, in which half of the antigen from the father is “foreign” to the mother, and the mother’s immune system will automatically remove it. However, the vast majority of women continue to have a normal pregnancy until full term because of the immune tolerance mechanisms that exist after pregnancy, of which the production of closed antibodies plays an important role. If there is a deficiency of closed antibodies, it can lead to miscarriage. Homozygous habitual miscarriage with insufficient production of closed antibodies can be treated with active immunotherapy through lymphocyte injections to produce and enhance closed antibodies in the body and reduce the chances of miscarriage. The current treatment success rate of this therapy is over 90%. Closure antibody test: Closure antibody is anti-husband lymphocyte antibody (APLA). Patients with recurrent spontaneous abortion need to be tested for closure antibody before and after immunotherapy by drawing 2ml of peripheral blood from the patient, separating the serum, and measuring it by ELISA, and if APLA is negative, immunotherapy is required. Immunotherapy method: active immunogen is preferred to husband lymphocytes, if husband is not suitable as immunogen donor (e.g. HBsAg positive or travel) then unrelated healthy individual is used, 30ml of donor peripheral blood is drawn for heparin anticoagulation, lymphocytes are routinely separated and extracted under aseptic conditions, washed 3 times with physiological saline and adjusted to lymphocyte concentration of (2-4) × 107/ml, and the amount of cell suspension was about 3 ml, which was injected into 6-8 spots in the skin of the left and right arms of the female partner by intradermal injection. A course of 4 injections was given every 2-3 weeks, and contraception was used during the treatment. The APLA is retested 2 weeks after the course of treatment. negative patients continue with the next course of immunotherapy until the APLA turns positive before considering conception. Positive patients are encouraged to become pregnant within 6 months, and if they do, they are immediately put on another course of maintenance therapy until about 16 weeks of gestation. Patients are also advised to take rest after pregnancy, avoid frequent sexual intercourse in early pregnancy, relieve mental tension, and pay attention to the early reaction of pregnancy. In order to ensure the treatment effect and safety of patients, the following conditions should be met: 1. negative closed antibody test; 2. normal chromosome of both spouses; 3. clear ABO and Rh blood group test of both spouses; 4. normal surface antibody to hepatitis B, hepatitis C, syphilis and HIV and TORCH test of both spouses, confirming no viral and other microbial infections; 5. normal liver and kidney function of both spouses; 6. Normal; 6. No endocrine abnormalities in the wife, normal immunoglobulin and thyroid function; 7. Normal reproductive tract and other gynecological examinations in the wife; 8. Both spouses in good health, no immune diseases, etc. Note: 1. The treatment should be carried out under the unified plan of the doctor; 2. In case of vaginal bleeding and other pre-eclampsia abortion after early pregnancy, the doctor should be contacted in time so as to keep the fetus in time; 3. It is recommended to cooperate with the antiretroviral treatment after early pregnancy; 4. If discomfort occurs during immunotherapy, the doctor should be contacted in time. Most patients have redness, swelling and hard nodules in the first treatment, which are normal immune reactions and will gradually decrease with the increase of treatment.